Asset
ZELECIMENT ROSTUDIRSEN
DYNE THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07608432 | phase3 | recruiting | 2026-06-01 | 2030-12-01 | Dyne Therapeutics | Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) |
| NCT05524883 | phase1_2 | active_not_recruiting | 2022-08-12 | 2031-09-01 | Dyne Therapeutics | Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping |
FDA applications (0)
This company has no applications containing this asset.